Novartis will have the go-ahead to begin marketing Adakveo, the first targeted therapy for sickle cell disease.
FDA Approves Crizanlizumab: Here Is A New Drug For Sickle Cell Disease
Novartis will have the go-ahead to begin marketing Adakveo, the first targeted therapy for sickle cell disease.